Subtopic Deep Dive
Clusterin as Cancer Biomarker
Research Guide
What is Clusterin as Cancer Biomarker?
Clusterin serves as a cancer biomarker through measurement of its serum and tissue levels for prognosis, diagnosis, and treatment monitoring in malignancies including breast, prostate, and bladder cancers.
Clusterin, a heterodimeric glycoprotein of 449 amino acids, exists in secreted and nuclear isoforms with opposing functions in cancer (Koltai, 2014, 149 citations). Studies validate its overexpression in tumor tissues and correlation with poor prognosis (Shannan et al., 2005, 326 citations). Over 10 papers from the list assess its utility in clinical settings, particularly for chemoresistance and oxidative stress sensing (Trougakos, 2013, 130 citations).
Why It Matters
Clusterin biomarker levels predict chemoresistance in cancers, guiding targeted therapies like clusterin inhibitors (Koltai, 2014). In bladder cancer, serum clusterin alongside urinary proteins enables non-invasive monitoring, reducing cystoscopy frequency (D'Costa et al., 2016, 92 citations). Elevated clusterin in pancreatic cancer-associated fibroblasts links to BRCA status and HSF1 signaling, informing stromal-targeted interventions (Shaashua et al., 2022). Reliable detection improves early diagnosis and personalized treatment in high-recurrence cancers like prostate and urothelial types (Li et al., 2011, 85 citations).
Key Research Challenges
Isoform-Specific Detection
Distinguishing secreted pro-survival clusterin from nuclear anti-cancer isoform complicates biomarker assays (Koltai, 2014). Validation requires tissue-specific proteomics to avoid false positives in serum tests (Trougakos, 2013). No standardized antibody panels exist across cancer types (Shannan et al., 2005).
Prognostic Validation Gaps
Clusterin levels correlate with progression but lack large cohort trials for survival prediction (Shannan et al., 2005, 326 citations). Integration with other markers like Apo-A1 in bladder cancer needs multi-omics confirmation (Li et al., 2011). Heterogeneity in tumor microenvironments confounds reliability (Marozzi et al., 2021).
Clinical Trial Translation
Inhibiting clusterin enhances chemosensitivity, yet phase III trials for biomarker-guided therapy remain absent (Koltai, 2014). Oxidative stress modulation via clusterin shows promise but requires imaging validation (Trougakos, 2013). Regulatory hurdles delay serum cutoffs for routine use (D'Costa et al., 2016).
Essential Papers
Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer
Batool Shannan, M. Seifert, Konstantin Leskov et al. · 2005 · Cell Death and Differentiation · 326 citations
Clusterin: a key player in cancer chemoresistance and its inhibition
Tomas Koltai · 2014 · OncoTargets and Therapy · 149 citations
Clusterin is a heterodimeric disulfide-linked glycoprotein (449 amino acids) isolated in the rat prostate after castration. It is widely distributed in different tissues and highly conserved in spe...
The Molecular Chaperone Apolipoprotein J/Clusterin as a Sensor of Oxidative Stress: Implications in Therapeutic Approaches - A Mini-Review
Ioannis P. Trougakos · 2013 · Gerontology · 130 citations
<b><i>Background:</i></b> Organisms are constantly exposed to physiological and environmental stresses and therefore require an efficient surveillance of genome and proteome...
Inflammation, Extracellular Matrix Remodeling, and Proteostasis in Tumor Microenvironment
Marina Marozzi, Arianna Parnigoni, Aide Negri et al. · 2021 · International Journal of Molecular Sciences · 114 citations
Cancer is a multifaceted and complex pathology characterized by uncontrolled cell proliferation and decreased apoptosis. Most cancers are recognized by an inflammatory environment rich in a myriad ...
N-cadherin upregulation mediates adaptive radioresistance in glioblastoma
Satoru Osuka, Dan Zhu, Zhaobin Zhang et al. · 2021 · Journal of Clinical Investigation · 93 citations
Glioblastoma (GBM) is composed of heterogeneous tumor cell populations, including those with stem cell properties, termed glioma stem cells (GSCs). GSCs are innately less radiation sensitive than t...
A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer
Jamie D'Costa, James Goldsmith, Jayne S. Wilson et al. · 2016 · Bladder Cancer · 92 citations
For over 80 years, cystoscopy has remained the gold-standard for detecting tumours of the urinary bladder. Since bladder tumours have a tendency to recur and progress, many patients are subjected t...
Involvement of Oxidative Stress in Occurrence of Relapses in Multiple Sclerosis: The Spectrum of Oxidatively Modified Serum Proteins Detected by Proteomics and Redox Proteomics Analysis
Ada Fiorini, Tatiana Koudriavtseva, Elona Bucaj et al. · 2013 · PLoS ONE · 87 citations
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system. Several evidences suggest that MS can be considered a multi-factorial disease in which bot...
Reading Guide
Foundational Papers
Start with Shannan et al. (2005, 326 citations) for comprehensive roles in cancer progression; Koltai (2014, 149 citations) for chemoresistance mechanisms; Trougakos (2013, 130 citations) for oxidative stress sensing.
Recent Advances
Shaashua et al. (2022) on BRCA-clusterin in pancreatic CAFs; Marozzi et al. (2021) on tumor microenvironment; D'Costa et al. (2016) for bladder urinary biomarkers.
Core Methods
ELISA/serum assays (D'Costa et al., 2016); IHC/tissue staining (Shannan et al., 2005); redox proteomics for modifications (Trougakos, 2013); proteomics for isoform separation (Li et al., 2011).
How PapersFlow Helps You Research Clusterin as Cancer Biomarker
Discover & Search
Research Agent uses searchPapers to retrieve 'Clusterin as Cancer Biomarker' yielding Shannan et al. (2005, 326 citations), then citationGraph maps 50+ citing works on chemoresistance, and findSimilarPapers expands to bladder cancer urinary biomarkers like D'Costa et al. (2016). exaSearch uncovers niche trials linking clusterin to BRCA-pancreatic stroma (Shaashua et al., 2022).
Analyze & Verify
Analysis Agent applies readPaperContent to extract clusterin isoform data from Koltai (2014), verifies prognostic claims via verifyResponse (CoVe) against Trougakos (2013), and runs PythonAnalysis on citation networks for statistical correlation (e.g., Pearson r on expression vs. survival). GRADE grading scores Shannan et al. (2005) as high evidence for progression biomarker.
Synthesize & Write
Synthesis Agent detects gaps in isoform-specific trials via gap detection, flags contradictions between pro/anti-cancer roles, and generates exportMermaid diagrams of clusterin pathways. Writing Agent uses latexEditText for biomarker review sections, latexSyncCitations for 20+ refs, and latexCompile for camera-ready manuscripts.
Use Cases
"Run stats on clusterin expression vs survival in provided cancer papers"
Research Agent → searchPapers (clusterin biomarker) → Analysis Agent → runPythonAnalysis (pandas survival curve from Shannan/Koltai data) → matplotlib plot + GRADE verification → researcher gets CSV export with p-values.
"Draft LaTeX review on clusterin prognostic value in bladder cancer"
Synthesis Agent → gap detection (post-2015 trials) → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (D'Costa 2016, Li 2011) → latexCompile → researcher gets PDF with figures.
"Find code for clusterin proteomics analysis in cancer datasets"
Research Agent → paperExtractUrls (Trougakos 2013) → paperFindGithubRepo → githubRepoInspect (redox proteomics scripts) → researcher gets annotated GitHub repos with R/Python for serum protein quantification.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (clusterin cancer 200+ papers) → citationGraph → DeepScan (7-step verify on top 20) → structured report with GRADE tables. DeepScan analyzes chemoresistance claims: readPaperContent (Koltai) → CoVe → runPythonAnalysis (dose-response curves). Theorizer generates hypotheses on clusterin-HSF1 interactions from Shaashua et al. (2022) + microenvironment papers.
Frequently Asked Questions
What defines clusterin as a cancer biomarker?
Clusterin qualifies as a biomarker via elevated serum/tissue levels correlating with cancer progression, chemoresistance, and poor prognosis in prostate, breast, and bladder tumors (Shannan et al., 2005; Koltai, 2014).
What methods measure clusterin in cancer?
ELISA quantifies serum clusterin; immunohistochemistry assesses tissue isoforms; proteomics detects oxidative modifications (Trougakos, 2013; D'Costa et al., 2016).
What are key papers on clusterin biomarkers?
Shannan et al. (2005, 326 citations) reviews roles in pathogenesis; Koltai (2014, 149 citations) details chemoresistance; Shaashua et al. (2022) links to pancreatic stroma.
What open problems exist?
Lack of isoform-specific assays, large-scale prognostic trials, and integration with imaging for real-time monitoring persist (Koltai, 2014; Trougakos, 2013).
Research Clusterin in disease pathology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Clusterin as Cancer Biomarker with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Clusterin in disease pathology Research Guide